Overview

Clinical Trial of Pioglitazone Treatment in Patients With Type 2 Diabetes Mellitus and Covid-19

Status:
Recruiting

Trial end date:
2021-04-10

Target enrollment:
0

Participant gender:
All

Summary

The treatment with pioglitazone added to the standard treatment of patients with DM2 hospitalized for COVID-19 may produce a decrease in the number of patients who progress to a second phase of severe systemic inflammation.

Phase:

Phase 4

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal

Treatments:

Pioglitazone

Criteria

Inclusion Criteria:

1. Adult patients > 18 years

2. Confirmed diagnosis of COVID-19 or high clinical suspicion according to current
criteria.

3. Diagnosis prior to admission of DM2.

4. Patients who provide their informed consent to participate in the study

Exclusion Criteria:

1. Under 18 years

2. Known hypersensitivity to the active ingredient or any of the drug's excipients.

3. Known history of heart failure or situation at the time of initiation of the heart
failure study.

4. Hepatic failure.

5. Dialysis

6. Situation of diabetic ketoacidosis at the start of the study.

7. Diabetes mellitus different from type 2.

8. Active bladder cancer or a history of bladder cancer

9. Hematuria

10. Patients included in another experimental study with another drug.

11. Admission to the Intensive Care Unit.

12. Patients requiring mechanical ventilation at the time of inclusion

13. Pregnancy

14. Lactation